These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 21424701)
21. A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation. Rinaldi DA; Kuhn JG; Burris HA; Dorr FA; Rodriguez G; Eckhardt SG; Jones S; Woodworth JR; Baker S; Langley C; Mascorro D; Abrahams T; Von Hoff DD Cancer Chemother Pharmacol; 1999; 44(5):372-80. PubMed ID: 10501910 [TBL] [Abstract][Full Text] [Related]
22. A phase 1 dose-escalation study of ARRY-520, a kinesin spindle protein inhibitor, in patients with advanced myeloid leukemias. Khoury HJ; Garcia-Manero G; Borthakur G; Kadia T; Foudray MC; Arellano M; Langston A; Bethelmie-Bryan B; Rush S; Litwiler K; Karan S; Simmons H; Marcus AI; Ptaszynski M; Kantarjian H Cancer; 2012 Jul; 118(14):3556-64. PubMed ID: 22139909 [TBL] [Abstract][Full Text] [Related]
23. Phase 1, open-label, dose escalation, safety, and pharmacokinetics study of ME-344 as a single agent in patients with refractory solid tumors. Bendell JC; Patel MR; Infante JR; Kurkjian CD; Jones SF; Pant S; Burris HA; Moreno O; Esquibel V; Levin W; Moore KN Cancer; 2015 Apr; 121(7):1056-63. PubMed ID: 25411085 [TBL] [Abstract][Full Text] [Related]
24. Phase I and pharmacokinetic study of a daily times 5 short intravenous infusion schedule of 9-aminocamptothecin in a colloidal dispersion formulation in patients with advanced solid tumors. Herben VM; van Gijn R; Schellens JH; Schot M; Lieverst J; Hillebrand MJ; Schoemaker NE; Porro MG; Beijnen JH; ten Bokkel Huinink WW J Clin Oncol; 1999 Jun; 17(6):1906-14. PubMed ID: 10561232 [TBL] [Abstract][Full Text] [Related]
25. Phase I dose finding studies of obatoclax (GX15-070), a small molecule pan-BCL-2 family antagonist, in patients with advanced solid tumors or lymphoma. Hwang JJ; Kuruvilla J; Mendelson D; Pishvaian MJ; Deeken JF; Siu LL; Berger MS; Viallet J; Marshall JL Clin Cancer Res; 2010 Aug; 16(15):4038-45. PubMed ID: 20538761 [TBL] [Abstract][Full Text] [Related]
26. A phase 1 and dose-finding study of LY2523355 (litronesib), an Eg5 inhibitor, in Japanese patients with advanced solid tumors. Wakui H; Yamamoto N; Kitazono S; Mizugaki H; Nakamichi S; Fujiwara Y; Nokihara H; Yamada Y; Suzuki K; Kanda H; Akinaga S; Tamura T Cancer Chemother Pharmacol; 2014 Jul; 74(1):15-23. PubMed ID: 24752449 [TBL] [Abstract][Full Text] [Related]
27. Discovery of allosteric inhibitors of kinesin spindle protein (KSP) for the treatment of taxane-refractory cancer: MK-0731 and analogs. Cox CD; Garbaccio RM Anticancer Agents Med Chem; 2010 Nov; 10(9):697-712. PubMed ID: 21235439 [TBL] [Abstract][Full Text] [Related]
28. A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced-stage solid cancers: a California Cancer Consortium Study. Chao J; Synold TW; Morgan RJ; Kunos C; Longmate J; Lenz HJ; Lim D; Shibata S; Chung V; Stoller RG; Belani CP; Gandara DR; McNamara M; Gitlitz BJ; Lau DH; Ramalingam SS; Davies A; Espinoza-Delgado I; Newman EM; Yen Y Cancer Chemother Pharmacol; 2012 Mar; 69(3):835-43. PubMed ID: 22105720 [TBL] [Abstract][Full Text] [Related]
29. Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. Mita MM; Mita AC; Chu QS; Rowinsky EK; Fetterly GJ; Goldston M; Patnaik A; Mathews L; Ricart AD; Mays T; Knowles H; Rivera VM; Kreisberg J; Bedrosian CL; Tolcher AW J Clin Oncol; 2008 Jan; 26(3):361-7. PubMed ID: 18202410 [TBL] [Abstract][Full Text] [Related]
30. Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors. Dees EC; Infante JR; Cohen RB; O'Neil BH; Jones S; von Mehren M; Danaee H; Lee Y; Ecsedy J; Manfredi M; Galvin K; Stringer B; Liu H; Eton O; Fingert H; Burris H Cancer Chemother Pharmacol; 2011 Apr; 67(4):945-54. PubMed ID: 20607239 [TBL] [Abstract][Full Text] [Related]
31. Phase I dose-escalation and pharmacokinetic study of ispinesib, a kinesin spindle protein inhibitor, administered on days 1 and 15 of a 28-day schedule in patients with no prior treatment for advanced breast cancer. Gomez HL; Philco M; Pimentel P; Kiyan M; Monsalvo ML; Conlan MG; Saikali KG; Chen MM; Seroogy JJ; Wolff AA; Escandon RD Anticancer Drugs; 2012 Mar; 23(3):335-41. PubMed ID: 22123335 [TBL] [Abstract][Full Text] [Related]
32. Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study results. Heath EI; Blumenschein GR; Cohen RB; Lorusso PM; Loconte NK; Kim ST; Ruiz-Garcia A; Chao RC; Wilding G Cancer Chemother Pharmacol; 2011 Sep; 68(3):703-12. PubMed ID: 21140147 [TBL] [Abstract][Full Text] [Related]
33. A phase I study of sunitinib combined with modified FOLFOX6 in patients with advanced solid tumors. Leong S; Eckhardt SG; Chan E; Messersmith WA; Spratlin J; Camidge DR; Diab S; Khosravan R; Lin X; Chow Maneval E; Lockhart AC Cancer Chemother Pharmacol; 2012 Jul; 70(1):65-74. PubMed ID: 22623210 [TBL] [Abstract][Full Text] [Related]
34. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Sandor V; Bakke S; Robey RW; Kang MH; Blagosklonny MV; Bender J; Brooks R; Piekarz RL; Tucker E; Figg WD; Chan KK; Goldspiel B; Fojo AT; Balcerzak SP; Bates SE Clin Cancer Res; 2002 Mar; 8(3):718-28. PubMed ID: 11895901 [TBL] [Abstract][Full Text] [Related]
35. Phase I study of PM00104 (Zalypsis®) administered as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors. Massard C; Margetts J; Amellal N; Drew Y; Bahleda R; Stephens P; Armand JP; Calvert H; Soria JC; Coronado C; Kahatt C; Alfaro V; Siguero M; Fernández-Teruel C; Plummer R Invest New Drugs; 2013 Jun; 31(3):623-30. PubMed ID: 22688291 [TBL] [Abstract][Full Text] [Related]
36. Phase I trial and pharmacokinetic study of pyrazoloacridine in children and young adults with refractory cancers. Berg SL; Blaney SM; Adamson PC; O'Brien M; Poplack DG; Arndt C; Blatt J; Balis FM J Clin Oncol; 1998 Jan; 16(1):181-6. PubMed ID: 9440741 [TBL] [Abstract][Full Text] [Related]
37. A Phase I Clinical, Pharmacokinetic, and Pharmacodynamic Study of Weekly or Every Three Week Ixabepilone and Daily Sunitinib in Patients with Advanced Solid Tumors. Montero AJ; Kwon D; Flores A; Kovacs K; Trent JC; Benedetto P; Rocha-Lima C; Merchan JR Clin Cancer Res; 2016 Jul; 22(13):3209-17. PubMed ID: 26864210 [TBL] [Abstract][Full Text] [Related]
38. A phase I study of BMS-690514 in Japanese patients with advanced or metastatic solid tumors. Nokihara H; Yamamoto N; Yamada Y; Yamada K; Hirata T; Goto Y; Tanioka M; Ikeda Y; Tamura T Cancer Chemother Pharmacol; 2012 Oct; 70(4):559-65. PubMed ID: 22878519 [TBL] [Abstract][Full Text] [Related]
39. Phase I clinical and pharmacokinetic study of S9788, a new multidrug-resistance reversal agent given alone and in combination with doxorubicin to patients with advanced solid tumors. Tranchand B; Catimel G; Lucas C; Sarkany M; Bastian G; Evene E; Guastalla JP; Négrier S; Rebattu P; Dumortier A; Foy M; Grossin F; Mazier B; Froudarakis M; Barbet N; Clavel M; Ardiet C Cancer Chemother Pharmacol; 1998; 41(4):281-91. PubMed ID: 9488597 [TBL] [Abstract][Full Text] [Related]
40. A phase I pharmacokinetic and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors. Mahadevan D; Plummer R; Squires MS; Rensvold D; Kurtin S; Pretzinger C; Dragovich T; Adams J; Lock V; Smith DM; Von Hoff D; Calvert H Ann Oncol; 2011 Sep; 22(9):2137-2143. PubMed ID: 21325451 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]